Background-American College of Cardiology (ACC) guidelines state that percutaneous coronary interventions (PCI) be performed at centers and by operators with high-volume (Ͼ400 yearly/center) whose historical and current risk-adjusted outcomes statistics are comparable to those reported in large registries. Tripler Army Medical Center is a low-volume treatment facility but has a geographic need and special mission requirement for providing this service. Methods and Results-We computed 30-day incidence of stent thrombosis, need for repeat revascularization, and all-cause mortality for all PCIs performed at Tripler from January 2002 through June 2008. The New York State Registry regression model was selected among 3 risk-adjustment models that we assessed in our patients. This model was used to compute expected mortality rate based on patient risk factors. The 30-day incidence of stent thrombosis and repeat revascularization was also determined, and the long-term incidence of these events was estimated with the Kaplan-Meier method as was survival. For all 546 PCI procedures, 30-day mortality was 1.47%, the incidence of stent thrombosis 2.1%, the incidence of any repeat revascularization 5.1%, and the combined event rate 5.9%. Based on risk factors used in the New York State Registry, our expected mortality was 1.93% and not significantly different from the observed rate. Although survival at 1 and 3 years appeared comparable with benchmarks at 94.6% and 89.3%, as did repeat revascularization rates at 13.0% and 21.4%, the incidence of stent thrombosis was regarded as high whether the definition included possible cases (3.2% and 3.9%) or only those regarded as definite or probable (2.7% and 3.1%). We did not identify any remediable risk factors for stent thrombosis, nor were we able to identify significant differences by year or by operator. However, visual inspection of a plot of deciles of New York State risk of death demonstrated 2 outlier cases among the 8 who died, who could have been considered candidates for thorough peer review. Conclusion-We recommend other low-volume interventional programs enter all patients undergoing PCI into a database, their own local registry even if not a national one such as the American College of Cardiology National Cardiovascular Data Registry, obtain information about survival and cardiac events during follow-up, compute and risk-adjust in-hospital or 30-day mortality, and use the objective assessment of risk in individual patients to identify outliers when outcome is adverse, and possibly as a means of triaging patients to appropriate therapy before choosing PCI. (Circ Cardiovasc Qual Outcomes. 2009;2:671-677.)
T he American College of Cardiology (ACC)/American Heart Association (AHA) Task Force presented an existential challenge to low-volume coronary interventional programs in its 2005 Update 1 with the following practice guidelines: (1) that both elective and emergent percutaneous coronary intervention (PCI) be performed at centers with high-volume (more than 400 procedures yearly) and at least 36 PCI procedures yearly for ST-segment elevation myocardial infarction (STEMI); (2) that individual operators perform Ն75 total PCI yearly including Ն11 for STEMI; (3) that an institution with a volume of fewer than 200 procedures per year, unless in a region that is underserved because of geography, should fully consider whether it should continue to offer this service; and (4) that a quality assessment process which conducts institutional and peer review take into account risk-adjustment, statistical power, and benchmarks.
Analysis of data from the National Inpatient Sample indicated that in the year 2000, 12% of PCI admissions in the United States were to hospitals with yearly interventional volumes of 200 to 400 procedures and another 4% with Ͻ200 procedures yearly. 2 The PCI program at Tripler Army Medical Center is among the latter as is that of most US military centers. Yet Tripler fulfills an important geographic need because of its location on the island of Oahu, and also fulfils a special mission, that of serving the active duty and retired military beneficiaries as well as their dependents and a Veterans population. In view of the existential challenge posed by the ACC/AHA Guidelines, we initiated an assessment of historical and current outcomes of our very lowvolume interventional program as a step toward performance improvement. Because outcomes are generally reported by large registries, healthcare systems, or large centers and not by low-volume centers, our methods and findings may be of interest to other programs fulfilling a geographic need or mission requirement but which also face the challenge of maintaining, documenting, and improving quality despite low volume.
Local Challenges in Implementation
There were several potential challenges to the implementation of this quality assessment program: the first was the identification of each patient who had undergone coronary intervention in our catheterization laboratory. This was greatly facilitated-and may not have been feasible without-a database which had been implemented in January 2002. This database had to be purchased commercially and designed for tracking procedures by the cardiology service because a hospital-wide database was not available for this purpose. The second challenge was determining the outcomes of our patients. This was greatly facilitated by the advent of electronic medical records as described in the subsequent section. The third challenge was that of determining which risk-adjustment method to adopt, and performing statistical analysis without an on-site professional statistician.
Design and Implementation of the Initiative

Institutional Review Board
This project was conducted as a quality assessment program, reviewed and approved as such-and not as human subjects research-by the Chair, the institutional review board, the Institutional Research Program Chief, and the Tripler Army Medical Center Command.
Data Collection
Demographic and procedural variables on all patients undergoing procedures in the Cardiac Catheterization Laboratory since January 1, 2002, have been entered into a secured database. Between that date and June 30, 2008, we identified 498 patients who underwent 565 PCI procedures during 546 30-day observation periods: 19 patients underwent staged or emergency reinterventions within 30 days of the index procedure, and any complications from these were attributed to the index procedure. Thus for 30-day outcomes analysis, there are 546 procedures. For analysis of long-term outcomes, there are 498 patients. The deidentified data were transferred to a spreadsheet to which other clinical and procedural variables were entered, and from which data were imported into statistical software (MedCalc and Stata). The spreadsheet was used to cross-check computations by statistical software when feasible. Electronic medical records used at this military facility and at the Veterans Administration Pacific Islands Healthcare System were reviewed for determination of survival status, repeat revascularization procedures, and comorbidities (ie, risk factors as detailed below).
Benchmark Selection (External Validation) for In-Hospital and 30-Day Outcomes
The risk adjustment model 3 for in-hospital death recommended by the National Cardiovascular Data Registry (NCDR) is based on the logistic regression analysis published in 2002 by Shaw et al. 4 We began by examining the results of that analysis and by performing a literature search, the results of which included 3 other publications we considered seminal: an analysis by Wu et al 5 Receiver operating characteristic curves were constructed and the areas under the curves computed using the statistical software; these were also performed on a spreadsheet (Excel) by computing the true positive fraction (sensitivity of predicting death at 30 days) and false-positive fraction (1Ϫspecificity) at progressively lower thresholds of probability of death for each model after rank ordering cases by the latter. The area under the curve for each regression model was computed, and the 3 compared using the method of Hanley and McNeil. 8 The areas under the receiver operating characteristic curves were similar (PϭNS) for the 3 models: 0.91 for the ACC 2002 model, 0.92 for the NY State model, and 0.90 for the ACC 2003 model.
The probability computed for each model for each patient was then used as the independent variable (or "risk factor") in 3 separate logistic regression analyses (univariate with inclusion of a constant ␤ o ) against the dependent variable, death (coded as 1 if it occurred, 0 otherwise). The resulting value of the coefficient ␤ 1 exponentiated (e ␤1 ) yields the odds ratio between the predicted probabilities of 1 and of 0.
Goodness of fit for each of the 3 models was assessed using the Ĉ statistic of Hosmer and Lemeshow, 9 which is obtained by calculating the Pearson 2 statistic from the 10ϫ2 table of observed and estimated binary outcomes (that is, 30-day death and survival) averaged within deciles of risk. All 3 models appeared to "fit" according to the Hosmer Lemeshow statistic: 5.48 (Pϭ0.71) for ACC 2002 model, 9.11 (Pϭ0.33) for the NY State model, and 10.6 (Pϭ0.22) for the ACC 2003 model. The relationship between "observed" and "fitted" probability for the NY State logistic model is shown in supplemental Figure II .
Although the model "fit" was not rejected for any of the 3, nor was the discriminatory ability significantly different among them (receiver operating characteristic curve areas), we selected the NY State model as our benchmark because of (1) the lack of linearity in the correlation between the 2 ACC models as noted above, (2) our desire to avoid overestimating expected mortality-per comparisons above-based on the ACC 2002 model, (3) the more current and more favorable mortality figure of the NY State model, and its use of fewer intraprocedural variables.
Benchmark Selection and Statistics for Outcomes Beyond 30 Days
We sought as a benchmark for long-term survival a registry of unselected patients including those presenting with acute STEMI, left main disease, either single-or multivessel disease, which included patients treated with bare metal or drug-eluting stents or no stents at all, and one which did not exclude patients who had undergone previous revascularization. Among several registries reviewed, the Swedish registry 10 most closely met those criteria. This registry was also chosen as a benchmark for repeat revascularization, the incidence of which was 15.2% and 16.5% for bare metal and drug-eluting stents-we used the weighted average at what appears from Figure 1 of their study to be at a median follow-up interval of approximately 21 months.
After survival, we considered freedom from stent thrombosis to be the most important outcome. To benchmark these results, we sought a similarly unselective registry-not a trial-that had clear and contemporary definitions of stent thrombosis. Among those reviewed the Western Denmark Heart Registry 11 appeared to best meet these criteria (the Swedish registry reported the incidence of myocardial infarction but not stent thrombosis). We also included the Dutch and Swiss trial because of the length of follow-up. 12 Competing risks analysis was performed for cumulative events. 13 To benchmark our repeat revascularization rates we selected the Swedish registry, 10 the Duke Databank, 14 the Western Denmark Heart Registry, 11 and-although it was limited to patients with multivessel disease-the data reported from the New York State Cardiac Surgery Reporting System and Percutaneous Coronary Intervention Reporting System. 15 Time-to-event analysis was performed by Kaplan-Meier product-limit method. Asymmetrical CIs around pointestimates were determined with the exponential method of Greenwood. For long-term outcomes that did not meet benchmark, a search for risk factors was performed among the ACC-NCDR and NY State and other variables listed above in the analysis of 30-day mortality. Stepwise logistic regression was used in the analysis of total cumulative events and Cox regression analysis for time-dependent ones.
Definitions
PCI was determined to have taken place if a wire was placed into a coronary vessel with the intent to intervene, and thus included procedures that failed. PCI was considered failed if there was failure to cross the lesion or if stenosis severity was Ͼ50% after the intervention. Mortality refers to all-cause mortality. A STEMI was considered acute if the patient developed STEMI while already in or presented to our facility where the diagnosis was made, and the decision was immediately made to proceed directly to the cath laboratory.
Heart failure was considered current if symptoms or radiographic signs existed during the PCI admission. Stent thrombosis was considered definite if stent occlusion was documented by angiography in the setting of an acute coronary syndrome. Stent thrombosis was considered probable in a patient having an ST-elevation myocardial infarction even if no angiography was performed, or who died without an another obvious cause within 30 days of PCI. Stent thrombosis was considered possible if the patient died suddenly more than 30 days after PCI without another known or strongly suspected cause such as in those with metastatic cancer, or those with such marked noncardiac disability that they required placement in a chronic care facility. We thus tried to conform to the Academic Research Consortium recommendation of "adjudicated definite and probable stent thrombosis." 16 The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Success of the Initiative
Thirty-Day Outcomes
No deaths occurred in the cardiac catheterization laboratory during the 6 and a half years reviewed. Eight deaths occurred before hospital discharge or during the first 30 days (100% follow-up) after PCI. Our observed mortality rate and the mortality rate expected on the basis of the NY State logistic regression model are shown with 95% CIs in Table 1 and were not significantly different. We found a significantly higher incidence of patients presenting with acute infarction, instability, shock, and current heart failure than in the NY When examined according to deciles of computed NY State probability of death, 2 observed deaths were identified as outliers (Figure 1) .
The 30-day mortality was 7.44% for the 81 patients presenting with acute STEMI, 0.43% for the remainder. PCI failed in 7.0% of procedures. There were only 2 instances of same-day repeat revascularization.
The 30-day combined outcome of death, definite or probable stent thrombosis, and repeat revascularization is shown with 95% CIs and a benchmark in Table 1 . 17 By univariate logistic regression, there was no significant effect of year of procedure (range, 0% to 7.5%) or operator (0% to 12.6%) on the combined 30-day major adverse outcome measure (major adverse coronary events [MACE], Table 3 ).
Outcomes After 30 Days
Information about survival was available on 86% of patients at 1 year and 53% at 3 years. Kaplan-Meier estimate of survival is shown with benchmarks in Figure 2 and with 95% CIs in Table 4 .
Cumulative incidences of possible or definite and probable stent thrombosis are shown with benchmarks in Figure 3 and with 95% CIs in Table 4 . The Kaplan-Meier estimated incidence of stent thrombosis, including those incidents considered to be only possible, was at 3.2% at 1 year (95% CI, 1.9% to 5.5%) and 3.9% at 3 years (95% CI, 2.4% to 6.5%).
Initial presentation with acute STEMI was not a statistically significant risk factor for cumulative stent thrombosis, nor was any of the risk factors among those used in the NY State model to predict 30-day mortality. Salvage PCI, a risk factor used in the ACC-NCDR Registry, was predictive in multivariate logistic regression analysis (odds ratio, 13; PϽ0.001). There was no statistically significant influence of operator on cumulative incidence of stent thrombosis. Year of procedure appeared to be of borderline significance (Pϭ0.044) ranging from 7.7% for patients having procedures in 2003 to 1.2% in 2005 (and no known incidences of stent thrombosis for patients undergoing procedures in 2008), but not when examined as a time-related variable using Cox regression analysis. At the time of stent thrombosis (definite, probable, or possible; nϭ17) 9 patients were still taking clopidogrel; 5 patients were not; in 3 patients it was uncertain.
Cumulative incidences of repeat revascularization of any vessel by PCI or surgery are shown with benchmarks in Figure 4 and with 95% CIs in Table 4 . Diabetes was a univariate predictor of repeat revascularization (odds ratio 2.2, PϽ0.01) as was failed PCI (odds ratio, 12; PϽ0.0001) and a totally occluded target vessel (odds ratio, 2.5; Pϭ0.013), though the latter variable was not retained in the multivariate model. Use of a drug-eluting stent reduced the subsequent cumulative incidence of revascularization (odds ratio, 0.47; Pϭ0.04).
Summary of the Experience, Future Directions, and Challenges
Performance improvement must be preceded by an assessment of outcomes and identification of risk factors for undesirable or adverse ones. We examined the incidence of death, stent thrombosis, and repeat revascularization, and then benchmarked those results against those of large national and international registries, using a risk adjustment model for 30-day mortality after comparing the performance of that model to 2 others. Our lessons learned are in brief:
1. A logistic regression model (equation) selected from 3 registries we assessed in our patients, allowed us to compute probability of early death in individual patients, discriminated between survivors and nonsurvivors, and permitted an adjustment of our institution's PCI procedural mortality. 2. Computed probabilities allowed us to identify 2 outliers, among 8 patients who died early, whose risk was several deciles lower than the others. These outliers and the operators who performed their procedures were candidates for particularly thorough review. 3. Probabilities computed for individual patients might be useful in the pre-PCI consent process, and perhaps also in the selection of a treatment strategy: percutaneous versus surgical versus conservative. 4. Stent thrombosis rates at our institution have been higher than benchmark, and need to be lower. Because we were unable to identify risk factors for stent thrombosis, we need to monitor our patients, their compliance with antiplatelet regimens long-term, and continue to look for risk factors and ways to reduce them. 5. Repeat revascularization at out institution was predicted by the presence of total occlusions and failed PCI as interdependent risk factors. 15 ‡Duke Databank, 14 §Western Denmark Heart Registry, 11 Dutch and Swiss Trial. 12 Table 4 and the Swedish registry (pink 10 ).
Thirty-Day Outcomes
We selected the NY State registry as our risk-adjustment model and benchmark for 30-day mortality for the reasons listed in the Methods section. Despite our low procedural volume, 30-day mortality was within the range reported in some other registries, 2,4 slightly higher (Pϭ0.055) before adjustment than that reported for the NY State Registry 5which is to our knowledge the lowest of any reported: 0.7% of 46 090 patients-but comparable (PϭNS) after adjustment for risk factors. Although reassuring, these statistical adjustments for risk also revealed that 2 of 8 deaths were outliers (Figure 1) . In a case-by-case review, the only NY State modeled risk factor for death identified in these 2 was acute STEMI. One had a failed attempt at recannalization of an occlusion of the ostium of the left anterior descending coronary, and despite aggressive hemodynamic support including an intraaortic balloon pump, was transferred for cardiac transplantation and died within 30 days of the failed PCI. The other developed a large infarction in the early postoperative phase of hip replacement, underwent stenting of the infarct-related dominant circumflex coronary, but died after developing subacute stent thrombosis despite balloon recannalization of the clotted stent and hemodynamic support with an intra-aortic balloon pump. Thus both of these outlier deaths were associated with failed procedures, one immediately, and the other within a week. Peer review of deaths after PCI in the future should include the computation of risk based on the model (NY State Registry) we selected and recommend to others, and a determination of whether those deaths are outliers in risk.
Our observed unadjusted 30-day incidence of stent thrombosis-but not repeat revascularization-appears higher (PϭNS) than in the benchmark we selected. Lindsay et al 17 have suggested that because procedural mortality rates are low and do not differentiate between low-and high-volume operators, that combined MACE of death, myocardial infarction, or symptom-driven revascularization at 1 month be used to assess performance. We used any revascularization rather than symptom-driven revascularization because we consider that an undesirable even if not necessarily adverse outcome. We could not statistically demonstrate a difference in the combined 1-month event rate across operators; however, the numbers of procedures ranged from only 1 to 30 for 10 of the operators (among whom there were 2 events in 91 total procedures). For the other 3 operators the 1-month event rates were 7.1% (of 56 procedures), 12.6% (of 119), and 3.9% (of 280). We know of no models that allow for risk adjustment of MACE other than death and recognize that our comparison to an external benchmark is an unadjusted one. We would propose, however, that if an operator's 30-day MACE rate is greater than 10% or represents outlier status among operators within an institution, careful review is warranted.
Outcomes After 30 Days
Survival long-term after PCI is generally the subject of research rather than quality assessment projects. The present quality assessment project was initiated after a surveyor for the Joint Commission asked "how are your stent patients doing-are they still alive?" Because many of our patients are referred from locations off of the island of Oahu (37% the 498 reported herein), we had not previously considered complete follow-up practical; however, the recent advent of Department of Defense-wide and Veterans Administration-wide electronic medical records enabled us to perform an electronic medical record review to be extended to off-island patients. Although survival of our patients during a median followup interval of 3 years appears within the range of benchmarks, we realize the wide CIs around our point estimates limit the precision of this assessment. The small number of patients surveyed, however, does not lessen the importance of our quality assessment, but rather adds motivation for it: given the existential challenge posed by the ACC/AHA guidelines, it is critical that those interventional programs that have a geographic or mission requirement to perform PCI despite low volume have a rigorous quality assessment and improvement program that includes shortterm and, as suggested by our Joint Commission surveyor, long-term outcomes.
Some authors addressing the subject of low operator and institutional volume have noted that although mortality is not adversely related, repeat revascularization is. 2, 17 We found that the most predictive risk factor for this was failed attempt at PCI which occurred in 7% of our PCI procedures, and believe the best way to avoid failure is judicious triage of cases with chronic total occlusion for PCI versus surgical intervention or medical therapy.
Definite or probable stent thromboses occurred within 30 days of PCI in 9 patients and also led to repeat revascularization in 7. Although we did not attempt to document the impact of any changes in technique on outcomes, and were not able to identify remediable risk factors for stent thrombosis, efforts to reduce this adverse outcome have included the routine use of high-pressure stent deployments; we also began to avoid complex bifurcation stenting in favor of stenting the main branch and using balloon-only angioplasty on any jeopardized side branch. We have not increased our usage of intravascular ultrasound to guide stent deployment and have not used it at all as of late 2005. Both latter practice trends are a manifestation of our belief that simpler is often safer. Given the importance of clopidogrel in the prevention of stent thrombosis, we began in 2007 to make documentation of stent type (drug-eluting or not) and adherence to clopidogrel therapy a performance improvement measure in our outpatient chart reviews.
We conclude that (1) low procedural volume is indeed problematic, (2) some low volume interventional programs fill an important need and may have good outcomes, (3) risk-adjustment models are imperfect but should be used not only to adjust outcome measures but to guide treatment strategy and identify individual outlier cases, and (4) that as stated in the ACC/AHA guidelines, "a quality assessment process which conducts institutional and peer review take[s] into account risk-adjustment, statistical power, and benchmarks" is an obligation.
